HEPA News and Press, Hepion Pharmaceuticals Inc. From 09/29/23

EDISON, N.J., Sept. 29, 2023 (GLOBE NEWSWIRE) -- Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA), a clinical stage biopharmaceutical company focused on artificial intelligence assisted therapeutic drug development for the treatment of non-alcoholic steatohepatitis (“NASH”), fibrotic dise...

QualTek Services Inc. (QTEKQ) is expected to report for Q2 2023 Amerityre Corp (AMTY) is expected to report for quarter end 2023-06-30 BYD Co - Class H (BYDDF) is expected to report for quarter end 2023-06-30 Shionogi & Co. Ltd. ADR (SGIOY) is expected to report for Q1 2024 Ea...

EDISON, N.J., Sept. 21, 2023 (GLOBE NEWSWIRE) -- Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA), a clinical stage biopharmaceutical company focused on Artificial Intelligence (“AI”)-driven therapeutic drug development for the treatment of non-alcoholic steatohepatitis (“NASH ...

- 850 cancer cell lines screened in Broad Institute’s PRISM lab - - Rencofilstat active on 220 cancer cell lines spanning 86% of cancer types – EDISON, N.J., Sept. 21, 2023 (GLOBE NEWSWIRE) -- Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA), a clinical stage biopharmaceutic...

2023-09-21 06:54:43 ET More on Aurinia Seeking Alpha’s Quant Rating on Aurinia Pharma Historical earnings data for Aurinia Pharma Aurinia: Strategic Alternatives Could Go Either Way For Stakeholders Aurinia spikes on Q2 earnings beat, guidance raise ...

- Research study demonstrates regulation of chromatin structure and cancer gene expression – - Findings to augment clinical trial in liver cancer - EDISON, N.J., Sept. 19, 2023 (GLOBE NEWSWIRE) -- Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA), a clinical stage biopharmaceutica...

Zovio Inc. (ZVOI) is expected to report for quarter end 2023-06-30 Sierra Grande Minerals Inc Ordinary Shares (SIERD) is expected to report for quarter end 2023-06-30 The Intergroup Corporation (INTG) is expected to report for Q1 2024 Fortescue Metals Group Ltd ADR (FSUGY) is expected...

– Proteomics analysis showed that rencofilstat improved aberrant protein profiles in IPF tissues – – Superior effects of rencofilstat alone and in combination with pirfenidone and nintedanib – EDISON, N.J., Sept. 14, 2023 (GLOBE NEWSWIRE) -- Hepion Phar...

Blue Water Biotech Inc. (BWV) is expected to report $-0.12 for Q2 2023 Lycos Energy Inc (MAAL) is expected to report for quarter end 2023-06-30 Esports Entertainment Group Inc. (GMBL) is expected to report $-2.92 for Q4 2023 SigmaTron International Inc. (SGMA) is expected to report fo...

2023-09-07 07:02:05 ET More on Hepion Pharmaceuticals Hepion Pharma NASH candidate meets phase 2 goal; up 68% Hepion climbs 39% on pre-clinical data for lead asset Hepion granted 180-day extension by Nasdaq to meet bid price requirements For furth...